HER2 as a therapeutic target in head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 21, Issue 3, 2015, Pages 526-533

  Pollock, Netanya I ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; METHOTREXATE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; DOWN REGULATION; DRUG EFFECT; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HER2 GENE; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HEAD AND NECK NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84922115628     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1432     Document Type: Review

References (66)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: cancer incidence and mortality worldwide: IARC CancerBase No. 10 [monograph on the Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [cited 2014 Sep 3].
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21 Suppl 7:vii252-61.
4. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
6. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
7. Vermorken JB, Trigo J, Hitt R, Koralewski P, az-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the ef ficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
8. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
9. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
10. Anderson NG, Ahmad T. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci 2002;7:d1926-40.
11. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
13. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-4.
14. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-74.
15. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007;29:655-64.
16. Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008;99:1589-94.
17. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008;15:1193-201.
18. Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, et al. Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib. Mol Cancer Ther 2013;12:1515-25.
19. Pardis S, Sardari Y, Ashraf MJ, Andisheh TA, Ebrahimi H, Purshahidi S, et al. Evaluation of tissue expression and salivary levels of HER2/neu in patients with head and neck squamous cell carcinoma. Iran J Otorhinolaryngol 2012;24:161-70.
20. Sardari Y, Pardis S, Tadbir AA, Ashraf MJ, Fattahi MJ, Ebrahimi H, et al. HER2/neu expression in head and neck squamous cell carcinoma patients is not signi fi cantly elevated. Asian Pac J Cancer Prev 2012;13:2891-6.
21. Hama T, Yuza Y, Suda T, Saito Y, Norizoe C, Kato T, et al. Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma. Clin ExpMetastasis 2012;29:19-25.
22. Ali MA, Gunduz M, Gunduz E, Tamamura R, Beder LB, Katase N, et al. Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. Cancer Invest 2010;28:495-500.
23. Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, El-Naggar AK, et al. HER- 2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121:1265-70.
24. Khademi B, Shirazi FM, Vasei M, Doroudchi M, Gandomi B, Modjtahedi H, et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlationwith prognostic markers in patients with head and neck tumors. Cancer Lett 2002;184:223-30.
25. Angiero F, Sordo RD, Dessy E, Rossi E, Berenzi A, Stefani M, et al. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? J Oral Pathol Med 2008;37:145-50.
26. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997;3:3-9.
27. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003;25:864-72.
28. Shiga H, Rasmussen AA, Johnston PG, Langmacher M, Baylor A, Lee M, et al. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck 2000;22:599-608.
29. Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003;63:1179-82.
30. Koynova DK, Tsenova VS, Jankova RS, Gurov PB, Toncheva DI. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J Cancer Res Clin Oncol 2005;131:199-203.
31. Tse GM, Yu KH, Chan AW, King AD, Chen GG, Wong KT, et al. HER2 expression predicts improved survival in patients with cervical nodepositive head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2009;141:467-73.
32. Khan AJ, King BL, Smith BD, Smith GL, Digiovanna MP, Carter D, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002;8:540-8.
33. Ibrahim SO, Lillehaug JR, Johannessen AC, Liavaag PG, Nilsen R, Vasstrand EN. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. Oral Oncol 1999;35:302-13.
34. Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011;105:618-27.
35. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011;17:5935-44.
36. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18:2336-43.
37. Uno M, Otsuki T, Kurebayashi J, Sakaguchi H, Isozaki Y, Ueki A, et al. Anti- HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 2001;94:474-9.
38. Schrader C, Boehm A, Reiche A, Diet A, Mozet C, Wichmann G. Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma. Anticancer Res 2012;32:3191-9.
39. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Renas-Elliott C, Martin AM, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-94.
40. Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010;23:957-63.
41. Arkhipov A, Shan Y, Kim ET, Dror RO, Shaw DE. Her2 activation mechanismreflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Elife 2013;2:e00708.
42. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, et al. Differential endocytic routing of homo- and heterodimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-97.
43. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 2001;61:6583-91.
44. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
45. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
46. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933-8.
47. Wolff A, Hammond E, Hicks D, Dowsett M, McShane L, Allison K, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31:3997-4013.
48. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura R, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50.
49. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000;86:269-75.
50. Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, et al. Multiple protein analysis of formalin-fixed and paraf fin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteomics 2013;12:2615-22.
51. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009;9:6.
52. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56.
53. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
54. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014;40:259-70.
55. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat Rev 2011;38:133-42.
56. Gillison ML, Glisson BS, O'Leary E, Murphy BA, Levine MA, Kies MS, et al. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J Clin Oncol 24:18s, 2006 (suppl; abstr 5511).
57. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013;19:5552-6.
58. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44.
59. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-87.
60. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplifi cation with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11.
61. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30:1426-47.
62. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
63. Harbeck N, Solca F, Gauler TC. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. Future Oncol 2014;10:21-40.
64. Williams J, Kim I, Ito E, Shi W, Yue S, Siu L, et al. Pre-clinical characterization of dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. PLoS ONE 2014;9:e9855.
65. Harrington KJ, Temam S, D'Cruz A, Jain MM, D'Onofrio I, Manikhas G, et al. Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 32:5s, 2014 (suppl; abstr 6005).
66. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, et al. A randomized, phase 2 study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25:1813-20.